Aortic aneurysm results from the weakening of the wall in the aorta and can turn into a serious medical emergency if ruptured. Aortic aneurysms occurring in the chest and lower abdomen are referred to as thoracic aortic aneurysm (TAA) and abdominal aortic aneurysm (AAA) respectively. The abdominal aneurysms are most commonly observed in men aged over 60 years with at least one or more risk factors such as high blood pressure, high cholesterol, obesity, family history, and other lifestyle-related disorders.
The thoracic aortic aneurysm, a medical condition with a weakening of upper aorta, develops slowly and mostly without any symptoms. Thus, diagnosis of thoracic aneurysms is comparatively difficult. Among available options, the most effective one is surgical procedure also called an aortic aneurysm repair. Open chest surgery for TAA, open abdomen surgery for AAA, endovascular aneurysm repair (EVAR) is the common surgical procedure for treating an aortic aneurysm.
Major factors driving the aortic aneurysm market is the increasing population of smokers and high incidence rate of lifestyle diseases. In addition, the growing geriatric population, technological advancements, and favorable reimbursement policy are other factors attributing to the market growth. Technological advancements in the field of minimally invasive surgery can be witnessed with the introduction of robotic surgery for a more precise and accurate treatment of abdominal aortic aneurysm with minimal side effects. However, lack of awareness about the disease among the population and associated risk is expected to hamper the market growth. For instance, the high mortality rate is observed due to endoleak which is a major complication that occurs when blood leaks into an aneurysm sac after endovascular aneurysm repair (EVAR) procedure.
The aortic aneurysm market is highly concentrated with three companies Medtronic PLC, Cook Medical, and W.L. Gore and Associates holding the major market share. Companies with limited geographical presence are applying different strategies for business expansion. For instance, In April 2018, MicroPort Scientific Corp. through its subsidiary, Endovascular Technology Corp., acquired Lombard Medical Limited and Lombard Medical Technologies GmbH to commercialize its two novel stent graft technologies Aorfix and Altura. In other acquisition, Endologix acquired Trivascular to broaden its product portfolio for increased visibility in the aortic aneurysm market. Other prominent players in the market are Terumo Corp., Endologix Inc., MicroPort Scientific Corporation, Maquet GmbH (Getinge Group), Jotec GmbH, Boston Scientific Corp., and Lombard Medical Technologies PLC.
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."